nature portfolio

| Corresponding author(s): | Jose M. Polo, Kanta Subbarao |
|----------------------------|------------------------------|
| Last updated by author(s): | 18 April 2023 |

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

| < ∙ | tっ | 1 | | Ηı | ~ |
|-----|----|---|-----|----|----|
| .) | ıd | ш | 1.5 | ıI | CS |

| For | all st | atistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section. |
|----------|-------------|--|
| n/a | Cor | nfirmed |
| | \boxtimes | The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement |
| | \boxtimes | A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly |
| | \boxtimes | The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section. |
| | \boxtimes | A description of all covariates tested |
| \times | | A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons |
| | \boxtimes | A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| | \boxtimes | For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable. |
| \times | | For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings |
| \times | | For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes |
| \times | | Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated |
| | ' | Our web collection on <u>statistics for biologists</u> contains articles on many of the points above. |

Software and code

Policy information about availability of computer code

Data collection

LightCycler 480 software (Roche, version 1.5.1.62), Leica application suite X version 3.7.1.21655 for DMi8, FLUOstar® Omega (BMG Labtech)

Data analysis

GraphPad Prism (v7), ImageJ (v1.8.0_112), Adobe Photoshop (version 21.2.3), base R(3.6.3), STAR aligner (v2.5.2), limma 3.42.2, tidyverse 1.3.0, trimmomatic 0.36, sabre 1.000, Subread v1.5.2, EdgeR v3.32.1, MADE4 v1.64.0, ComplexHeatmap v2.6.2, ggplot2 v3.3.5, ggrepel v0.9.1, Seurat v4.2.1, Monocle3 v1.3.1, dplyr v1.0.10, EdgeR v3.40.0, sva packagae v3.46

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio <u>guidelines for submitting code & software</u> for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

Raw and processed next generation sequencing datasets were deposited at the Gene Expression Omnibus (GEO) repository with the following accession number: GSE185471

Human research participants

Policy information about studies involving human research participants and Sex and Gender in Research.

This study utilised placental tissues obtained from pregnant women, so participants were females only, and sex and gender Reporting on sex and gender analysis does not apply to this study.

Population characteristics Nothing to add here

Recruitment Women undergoing elective termination of pregnancy were recruited, with exclusion criteria of known fetal abnormalities or participants <18 years of age. All participants provided informed written consent on placental tissue donation, and there is no self-selection bias or other biases that may affect the result.

Ethics oversight Ethics approval for the use of first trimester human placental tissues for research was obtained from the Human Ethics Committee at Monash Health, Melbourne, Australia (RES-19-0000-399A).

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

X Life sciences

Sample size

Replication

| Please select the one below that is the best fit for | your research. If you are not sure, | . read the appropriate sections be | fore making your selection. |
|--|-------------------------------------|------------------------------------|-----------------------------|
| | | | |

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Behavioural & social sciences

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

We did not involve statistical methods to pre-determine the sample size, this was determined based on previous experience (Liu et al., Nature 2020) and other similar studies (Karvas et al., Cell Stem Cell 2022; Ruan et al., Cell Reports Medicine 2022). We generated data using 2 iTSC

Ecological, evolutionary & environmental sciences

cell lines in multiple runs

of differentiation and infection (Representative graphs from 2 independent experiments showing n=3 separate infection replicates).

Data exclusions No data were excluded

Each experiment was repeated independently at least twice successfully, with each experiment containing a minimum of 3 separate infection

Experiments were not randomized. Randomization of samples were not necessary to our study as we needed to determine virus vs control in Randomization

most cases and our sample sizes were typically low.

The investigators were not blinded during data collection and analysis, as neither human/animal studies or specific grouping were involved in Blinding this manuscript

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

| Materials & experimental systems n/a Involved in the study |
|--|
| Antibodies ChIP-seq Eukaryotic cell lines Flow cytometry Palaeontology and archaeology MRI-based neuroimaging Animals and other organisms Clinical data Dual use research of concern Antibodies Antibodies Antibodies Antibodies Antibodies Antibody, Company, Catalogue Number, Lot Number, Dilution: Mouse anti-GATA2 gG2a clone 2D11, Sigma-Aldrich Cat# WH0002624M1 Lot G2151-2D11, 1:100 |
| Eukaryotic cell lines Flow cytometry Palaeontology and archaeology MRI-based neuroimaging Animals and other organisms Clinical data Dual use research of concern Antibodies For Immunostaining: Antibody, Company, Catalogue Number, Lot Number, Dilution: Mouse anti-GATA2 IgG2a clone 2D11, Sigma-Aldrich Cat# WH0002624M1 Lot G2151-2D11, 1:100 |
| Eukaryotic cell lines Flow cytometry Palaeontology and archaeology MRI-based neuroimaging Animals and other organisms Clinical data Dual use research of concern Antibodies For Immunostaining: Antibody, Company, Catalogue Number, Lot Number, Dilution: Mouse anti-GATA2 IgG2a clone 2D11, Sigma-Aldrich Cat# WH0002624M1 Lot G2151-2D11, 1:100 |
| Palaeontology and archaeology MRI-based neuroimaging Animals and other organisms Clinical data Dual use research of concern Antibodies Antibodies For Immunostaining: Antibody, Company, Catalogue Number, Lot Number, Dilution: Mouse anti-GATA2 IgG2a clone 2D11, Sigma-Aldrich Cat# WH0002624M1 Lot G2151-2D11, 1:100 |
| Animals and other organisms Clinical data Dual use research of concern Antibodies Antibodies used For Immunostaining: Antibody, Company, Catalogue Number, Lot Number, Dilution: Mouse anti-GATA2 IgG2a clone 2D11, Sigma-Aldrich Cat# WH0002624M1 Lot G2151-2D11, 1:100 |
| Clinical data Dual use research of concern Antibodies Antibodies used For Immunostaining: Antibody, Company, Catalogue Number, Lot Number, Dilution: Mouse anti-GATA2 IgG2a clone 2D11, Sigma-Aldrich Cat# WH0002624M1 Lot G2151-2D11, 1:100 |
| Dual use research of concern Antibodies Antibodies used For Immunostaining: Antibody, Company, Catalogue Number, Lot Number, Dilution: Mouse anti-GATA2 IgG2a clone 2D11, Sigma-Aldrich Cat# WH0002624M1 Lot G2151-2D11, 1:100 |
| Antibodies Antibodies used For Immunostaining: Antibody, Company, Catalogue Number, Lot Number, Dilution: Mouse anti-GATA2 IgG2a clone 2D11, Sigma-Aldrich Cat# WH0002624M1 Lot G2151-2D11, 1:100 |
| Antibodies used For Immunostaining: Antibody, Company, Catalogue Number, Lot Number, Dilution: Mouse anti-GATA2 IgG2a clone 2D11, Sigma-Aldrich Cat# WH0002624M1 Lot G2151-2D11, 1:100 |
| Antibody, Company, Catalogue Number, Lot Number, Dilution: Mouse anti-GATA2 IgG2a clone 2D11, Sigma-Aldrich Cat# WH0002624M1 Lot G2151-2D11, 1:100 |
| Mouse anti-GATA2 IgG2a clone 2D11, Sigma-Aldrich Cat# WH0002624M1 Lot G2151-2D11, 1:100 |
| |
| ivegative Control Nappit Infinitioglobulin Fraction, A0003, Dako, 1.10000 |
| Mouse IgG1 Culture supernatant, X0931, Agilent Technologies, 1:10000 |
| Goat Anti-Rabbit IgG Antibody (H+L), Biotinylated, BA-1000, Vector Laboratories, 1:1000 |
| Horse Anti-Mouse IgG Antibody (H+L), Biotinylated, BA-2000, Vector Laboratories, 1:1000 |
| Mouse anti-HCG IgG1 clone 5H4-E2, abcam , ab9582 Lot GR3285169-1, 1:200 |
| Mouse anti-dsRNA lgG2a clone rJ2, Merck, MABE1134 Lot 3543801, 1:200 |
| Rabbit anti-ACE2 IgG, abcam, ab15348 Lot GR3333640-15, 1:200 |
| Mouse anti-GATA3 IgG1 clone 1A12-1D9, Invitrogen, MA1-028, 1:100 |
| anti-HLA G IgG1 clone MEM-G/1, abcam, ab7759 Lot GR3262011-5, 1:50 |
| Rabbit anti-SDC1 IgG, Cell Signaling Technology, Cat# 12922 Lot 1, 1:400 |
| Rabbit anti-anti-DAB2 IgG, ab76253, abcam, 1:100 |
| Rabbit anti-MMP2 IgG, Cell Signaling Technology, Cat# 40994, 1:100 |
| Mouse anti-SARS-CoV-2 Nucleocapsid IgG, MyBioSource, MBS154642, 1:300 Goat anti-human IgG H&L (HRP), abcam, ab6858, 1:5000 |

Goat anti-mouse IgG1 Alexa Fluor 488, Invitrogen, Thermo Fisher Scientific, A21121 Lot 1964382, 1:400 Goat anti-rabbit IgG Alexa Fluor 555, Invitrogen, Thermo Fisher Scientific, A21428 Lot 1786491, 1:400 Goat anti-mouse IgG2a Alexa Fluor 555, Invitrogen, Thermo Fisher Scientific, A21137 Lot 1899521, 1:400 Donkey anti-rabbit IgG Alexa Fluor 647, Invitrogen, Thermo Fisher Scientific, A31573 Lot 1903516, 1:400 Donkey anti-mouse IgG Alexa Fluor 555, Invitrogen, Thermo Fisher Scientific, A31570, Lot 1850121, 1:400

For Western Blot:

Mouse Anti-GAPDH IgG1 clone 6C5, Merck, MAB374 Lot 3018865, 1:5000 Goat anti-Mouse IgG 680LT, LI-COR, 926-68020 Lot C20531-05, 1:50000 Goat anti-Rabbit IgG 800CW, LI-COR, 925-32211 Lot C80925-01, 1:50000

Validation

Antibodies obtained from the commercial source were validated by the suppliers, detailed validation analysis relevant literatures are provided on the company website for the products used in this study. Some antibodies were validated in a previously published study as indicated in methods or relevant literature was cited.

GATA2 (WH0002624M1) https://www.sigmaaldrich.com/catalog/product/sigma/wh0002624m1

Negative Control Rabbit Immunoglobulin Fraction (X0903) https://www.agilent.com/cs/library/packageinsert/public/SSX0903RUO 01.pdf

Mouse IgG1 Culture supernatant (X0931) https://www.agilent.com/cs/library/packageinsert/public/102432002.PDF

Anti-Rabbit IgG Antibody (H+L), Biotinylated (BA-1000) https://vectorlabs.com/products/antibodies/biotinylated-goat-anti-rabbit-igg Anti-Mouse IgG Antibody (H+L), Biotinylated (BA-2000) https://vectorlabs.com/products/antibodies/biotinylated-horse-anti-mouse-igg

HCG (ab9582) https://www.abcam.com/hcg-beta-antibody-5h4-e2-ab9582.html

 $ds RNA \ (MABE1134) \ https://www.merckmillipore.com/AU/en/product/Anti-ds RNA-Antibody-clone-rJ2, MM_NF-MABE1134-25 ULACE2 \ (ab15348) \ https://www.abcam.com/ace2-antibody-ab15348.html$

GATA3 (MA1-028) https://www.thermofisher.com/antibody/product/GATA3-Antibody-clone-1A12-1D9-Monoclonal/MA1-028 HLA G (ab7759) https://www.abcam.com/hla-g-antibody-mem-g1-ab7759.html

SDC1 (Cat# 12922) https://www.cellsignal.com/products/primary-antibodies/syndecan-1-d4y7h-rabbit-mab/12922

 $MMP2 \ (Cat \# \ 40994) \ https://www.cellsignal.com/products/primary-antibodies/mmp-2-d4m2n-rabbit-mab/40994$

SARS-CoV-2 Nucleocapsid (MBS154642) https://www.mybiosource.com/monoclonal-covid-19-antibody/covid-19-nucleocapsid-np-coronavirus/154642

Goat anti-Human IgG H&L (HRP) https://www.abcam.com/products/secondary-antibodies/goat-human-igg-hl-hrp-ab6858.html Goat anti-mouse IgG1 Alexa Fluor 488 (A21121) https://www.thermofisher.com/antibody/product/Goat-anti-Mouse-IgG1-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A-21121

Goat anti-rabbit IgG Alexa Fluor 555 (A21428) https://www.thermofisher.com/antibody/product/Goat-anti-Rabbit-IgG-H-L-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A-21428

Goat anti-mouse IgG2a Alexa Fluor 555 (A21137) https://www.thermofisher.com/antibody/product/Goat-anti-Mouse-IgG2a-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A-21137

Donkey anti-rabbit IgG Alexa Fluor 647 (A31573) https://www.thermofisher.com/antibody/product/Donkey-anti-Rabbit-IgG-H-L-Highly-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A-31573

Donkey anti-mouse IgG Alexa Fluor 555 (A31570)

https://www.thermofisher.com/antibody/product/Donkey-anti-Mouse-IgG-H-L-Highly-Cross-Adsorbed-Secondary-Antibody-Antib

Polyclonal/A-31570

GAPDH (MAB374) https://www.merckmillipore.com/AU/en/product/Anti-Glyceraldehyde-3-Phosphate-Dehydrogenase-Antibody-clone-6C5.MM NF-MAB374

Goat anti-mouse IgG 680LT (926-68020) https://www.licor.com/bio/reagents/irdye-680lt-goat-anti-mouse-igg-secondary-antibody Goat anti-rabbit IgG 800CW (925-32211) https://www.licor.com/bio/reagents/irdye-800cw-goat-anti-rabbit-igg-secondary-antibody

Eukaryotic cell lines

Policy information about <u>cell lines and Sex and Gender in Research</u>

Cell line source(s)

Human iTSC lines were previously generated as described in Liu et al., Nature 2020. (https://doi.org/10.1038/s41586-020-2734-6). iTSCs were generated using human fibroblasts sourced from ThermoFisher (Catalogue number, C-013-5C and lot#1528526 for 55F and lot#1569390 for 32F. Vero cells (Cat no. CCL-81) and Calu-3 cells (Cat no. HTB-55) were purchased from ATCC. Vero E6-TMPRSS2 (Cat no. JCRB1819) were purchased from CellBank Australia. Expi293 cells (Cat no. 14527) were purchased from Thermo Fisher Scientific. Ishikawa cells were sourced from Sigma-Aldrich (Catalogue number, 99040201, lot #14B013). FT008 primary cell lines were derived from the tissue consented by patients. However, as agreed in the initial ethics to receive the cells, the sex of the donor was not disclosed. However, we have analyzed sequencing data and found their genotype to be male.

Authentication

The human fibroblasts, Vero cells, Calu-3 cells, Vero E6-TMPRSS2, Expi293 and Ishikawa cells have been authenticated by the manufacturer's company via assays such as cellular morphology, STR profilling, mycoplasma testing, sterility testing or growth profile as stated in the certificate of analysis. The iTSCs and FT008 have been also authenticated in-house by immunostaining, qPCR, RNA-seq.

Mycoplasma contamination

Furthermore, all cell lines were regularly tested and were mycoplasma negative.

Commonly misidentified lines (See <u>ICLAC</u> register)

No commonly misidentified cell lines were used in this study.